memo

Report on the latest developments in Bruton’s tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

Chat with BeiGene

Close